SE504074C2 - Proteinberedning för subkutan, intramuskulär eller intradermal administrering - Google Patents

Proteinberedning för subkutan, intramuskulär eller intradermal administrering

Info

Publication number
SE504074C2
SE504074C2 SE9302308A SE9302308A SE504074C2 SE 504074 C2 SE504074 C2 SE 504074C2 SE 9302308 A SE9302308 A SE 9302308A SE 9302308 A SE9302308 A SE 9302308A SE 504074 C2 SE504074 C2 SE 504074C2
Authority
SE
Sweden
Prior art keywords
factor viii
subcutaneous
intramuscular
preparation
viii
Prior art date
Application number
SE9302308A
Other languages
English (en)
Swedish (sv)
Other versions
SE9302308L (sv
SE9302308D0 (sv
Inventor
Jack Spira
Lars Widlund
Thomas Oesterberg
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20390516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE504074(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Priority to SE9302308A priority Critical patent/SE504074C2/sv
Publication of SE9302308D0 publication Critical patent/SE9302308D0/xx
Priority to ZA942035A priority patent/ZA942035B/xx
Priority to MX9402339A priority patent/MX9402339A/es
Priority to DK94915722.6T priority patent/DK0710114T4/da
Priority to EP94915722A priority patent/EP0710114B2/de
Priority to ES94915722T priority patent/ES2193159T5/es
Priority to CA002163112A priority patent/CA2163112C/en
Priority to AT94915722T priority patent/ATE233099T1/de
Priority to AU67627/94A priority patent/AU6762794A/en
Priority to JP50398795A priority patent/JP3827713B2/ja
Priority to DE69432179T priority patent/DE69432179T3/de
Priority to PCT/SE1994/000297 priority patent/WO1995001804A1/en
Priority to US08/564,161 priority patent/US5972885A/en
Priority to SE9401105A priority patent/SE9401105D0/
Priority to PT94915722T priority patent/PT710114E/pt
Publication of SE9302308L publication Critical patent/SE9302308L/
Publication of SE504074C2 publication Critical patent/SE504074C2/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SE9302308A 1993-07-05 1993-07-05 Proteinberedning för subkutan, intramuskulär eller intradermal administrering SE504074C2 (sv)

Priority Applications (15)

Application Number Priority Date Filing Date Title
SE9302308A SE504074C2 (sv) 1993-07-05 1993-07-05 Proteinberedning för subkutan, intramuskulär eller intradermal administrering
ZA942035A ZA942035B (en) 1993-07-05 1994-03-23 Protein formulation
MX9402339A MX9402339A (es) 1993-07-05 1994-03-30 Formulacion de proteina.
PT94915722T PT710114E (pt) 1993-07-05 1994-03-31 Formulacao do factor viii de coagulacao
SE9401105A SE9401105D0 (sv) 1993-07-05 1994-03-31 Formulation
AT94915722T ATE233099T1 (de) 1993-07-05 1994-03-31 Eine formulierung des gerinnungsfaktors viii
DE69432179T DE69432179T3 (de) 1993-07-05 1994-03-31 Eine formulierung des gerinnungsfaktors viii
ES94915722T ES2193159T5 (es) 1993-07-05 1994-03-31 Una formulación de factor de coagulación viii.
CA002163112A CA2163112C (en) 1993-07-05 1994-03-31 A coagulation factor viii formulation
DK94915722.6T DK0710114T4 (da) 1993-07-05 1994-03-31 Koagulationsfaktor VIII-formulering
AU67627/94A AU6762794A (en) 1993-07-05 1994-03-31 A coagulation factor viii formulation
JP50398795A JP3827713B2 (ja) 1993-07-05 1994-03-31 凝固因子ｖｉｉｉからなる医薬製剤
EP94915722A EP0710114B2 (de) 1993-07-05 1994-03-31 Eine formulierung des gerinnungsfaktors viii
PCT/SE1994/000297 WO1995001804A1 (en) 1993-07-05 1994-03-31 A coagulation factor viii formulation
US08/564,161 US5972885A (en) 1993-07-05 1994-03-31 Method for treatment of hemophilia by extravascular administration of factor VIII deletion derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9302308A SE504074C2 (sv) 1993-07-05 1993-07-05 Proteinberedning för subkutan, intramuskulär eller intradermal administrering

Publications (3)

Publication Number Publication Date
SE9302308D0 SE9302308D0 (sv) 1993-07-05
SE9302308L SE9302308L (sv) 1995-01-06
SE504074C2 true SE504074C2 (sv) 1996-11-04

Family

ID=20390516

Family Applications (2)

Application Number Title Priority Date Filing Date
SE9302308A SE504074C2 (sv) 1993-07-05 1993-07-05 Proteinberedning för subkutan, intramuskulär eller intradermal administrering
SE9401105A SE9401105D0 (sv) 1993-07-05 1994-03-31 Formulation

Family Applications After (1)

Application Number Title Priority Date Filing Date
SE9401105A SE9401105D0 (sv) 1993-07-05 1994-03-31 Formulation

Country Status (14)

Country Link
US (1) US5972885A (de)
EP (1) EP0710114B2 (de)
JP (1) JP3827713B2 (de)
AT (1) ATE233099T1 (de)
AU (1) AU6762794A (de)
CA (1) CA2163112C (de)
DE (1) DE69432179T3 (de)
DK (1) DK0710114T4 (de)
ES (1) ES2193159T5 (de)
MX (1) MX9402339A (de)
PT (1) PT710114E (de)
SE (2) SE504074C2 (de)
WO (1) WO1995001804A1 (de)
ZA (1) ZA942035B (de)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7253262B2 (en) 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US7244824B2 (en) 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
SE9502285D0 (sv) * 1995-06-22 1995-06-22 Pharmacia Ab Improvements related to injections
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US7560107B2 (en) * 1996-06-26 2009-07-14 Emory University Modified factor VIII
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
US7223845B2 (en) 1998-06-16 2007-05-29 The Board Of Regents Of The University Of Oklahoma Synthetic glycosulfopeptides and methods of synthesis thereof
US20030143662A1 (en) 1998-06-16 2003-07-31 Cummings Richard D. Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof
MXPA00012586A (es) * 1998-06-16 2004-05-21 Univ Oklahoma Glicosulfopeptidos y metodos de sintesis y uso de los mismos.
RU2244556C2 (ru) 1999-02-22 2005-01-20 Юниверсити Оф Коннектикут Новые не содержащие альбумин составы фактора viii
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
CA2788505C (en) * 2003-02-26 2018-09-04 Nektar Therapeutics Polymer-factor viii moiety conjugates
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
CA2465004A1 (en) * 2003-05-19 2004-11-19 National Institute For Biological Standards And Control Composition
CN1266144C (zh) * 2003-09-01 2006-07-26 上海凯曼生物科技有限公司 黄芩甙和黄芩甙元的用途和剂型
ES2229931B1 (es) * 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
DE102004005095A1 (de) 2004-01-27 2005-09-22 Coty B.V. Kosmetische Zusammensetzung mit wasserbeständiger Parfümkomponente
EP1750733B1 (de) * 2004-05-03 2013-12-11 Emory University Verfahren zur verabreichung von schweine b-domänenlosem fviii
SI3130601T1 (sl) * 2004-11-12 2020-11-30 Bayer Healthcare Llc Usmerjena modifikacija FVIII
TWI264608B (en) * 2005-04-08 2006-10-21 Delta Electronics Inc Light tunnel module
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US8637007B2 (en) 2006-12-15 2014-01-28 Baxter International Inc. Factor VIIa-polysialic acid conjugate having prolonged in vivo half-life
CA2690218C (en) 2007-06-13 2017-02-28 Csl Behring Gmbh Use of vwf stabilized fviii preparations and of vwf preparations without fviii for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
JP5779780B2 (ja) 2008-11-07 2015-09-16 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 第ｖｉｉｉ因子製剤
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
US10172949B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
PL3266463T3 (pl) 2009-06-09 2024-03-18 Prolong Pharmaceuticals, LLC Kompozycje hemoglobiny
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
ES2856055T3 (es) 2009-07-27 2021-09-27 Baxalta GmbH Glicopolisialilación de proteínas diferentes de las proteínas de coagulación de la sangre
ES2590679T3 (es) 2009-07-27 2016-11-23 Lipoxen Technologies Limited Glicopolisialilación de proteínas diferentes a proteínas de coagulación de la sangre
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CA2769326A1 (en) 2009-07-27 2011-02-10 Baxter International Inc. Blood coagulation protein conjugates
KR20120061898A (ko) * 2009-08-20 2012-06-13 체에스엘 베링 게엠베하 출혈성 장애의 치료요법 및 예방 치료에 있어서의 비정맥내 투여를 위한 알부민 융합 응고 인자
WO2011028229A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
CA2782424C (en) 2009-12-06 2021-07-27 Biogen Idec Hemophilia Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
US20130216513A1 (en) 2010-07-09 2013-08-22 Biogen Idec Hemophilia Inc. Chimeric Clotting Factors
CN104788557A (zh) * 2010-09-15 2015-07-22 诺沃—诺迪斯克有限公司 具有减少的细胞摄取的因子viii变体
SG10201509149VA (en) 2010-11-05 2015-12-30 Baxter Int A new variant of antihemophilic factor viii having increased specific activity
KR102025442B1 (ko) 2010-12-22 2019-09-25 박스알타 인코퍼레이티드 단백질에 수용성 지방산 유도체를 접합하기 위한 물질 및 방법
EP2709648A4 (de) 2011-05-19 2015-04-08 Geysen Hendrik M Verbindungen zur bindung an den erythropoietinrezeptor
HUE039317T2 (hu) * 2011-06-10 2018-12-28 Baxalta GmbH Koagulációs betegség kezelése rekombináns VWF adagolásával
US9486507B2 (en) 2011-06-10 2016-11-08 Biogen Ma Inc. Pro-coagulant compounds and methods of use thereof
WO2013009627A2 (en) 2011-07-08 2013-01-17 Biogen Idec Hemophilia Inc. Factor viii chimeric and hybrid polypeptides, and methods of use thereof
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
AU2012318303B2 (en) 2011-10-18 2015-09-03 Csl Behring Gmbh Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of Factor VIII
KR20140083036A (ko) 2011-10-18 2014-07-03 체에스엘 베링 게엠베하 인자 ｖｉｉｉ의 생체이용률을 향상시키기 위한 황산화 글리코사미노글리칸의 용도
PT2804623T (pt) 2012-01-12 2019-11-18 Bioverativ Therapeutics Inc Polipéptidos quiméricos do fator viii e suas utilizações
ES2899848T3 (es) 2012-01-12 2022-03-15 Bioverativ Therapeutics Inc Reducción de la inmunogenicidad contra el factor VIII en individuos sometidos a una terapia con factor VIII
LT3564260T (lt) 2012-02-15 2023-01-10 Bioverativ Therapeutics Inc. Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
JP2015525222A (ja) 2012-06-08 2015-09-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． キメラ性凝固因子
EP4079316A1 (de) 2012-06-08 2022-10-26 Bioverativ Therapeutics Inc. Prokoagulatorische verbindungen
EP3404105A1 (de) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Einkettige faktor-viii-polypeptide exprimierende zelllinie und verwendungen davon
BR112015000267B1 (pt) 2012-07-11 2023-01-24 Bioverativ Therapeutics Inc. Proteínas quiméricas, e composição farmacêutica
EP2877202A4 (de) 2012-07-25 2016-06-01 Biogen Ma Inc Blutfaktorüberwachungstest und verwendungen davon
EP2908847B1 (de) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Verfahren zur verwendung einer festgelegten dosis eines blutgerinnungsfaktors
EP3943102A1 (de) 2012-10-30 2022-01-26 Bioverativ Therapeutics Inc. Verfahren zur verwendung von fviii-polypeptid
FI2956477T4 (fi) 2013-02-15 2024-04-24 Bioverativ Therapeutics Inc Optimoitu tekijä viii:n geeni
UY35462A (es) 2013-03-15 2014-10-31 Biogen Idec Inc Formulación de un polipéptido del factor viii.
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
EP2989123A4 (de) * 2013-04-22 2016-10-12 Scripps Research Inst Verfahren und zusammensetzungen zur behandlung von blutungsstörungen
EP2796145B1 (de) 2013-04-22 2017-11-01 CSL Ltd. Ein kovalenter komplex bestehend aus von willebrand und faktor viii verbunden mit einer disulfidbrücke
NZ713904A (en) 2013-06-28 2022-02-25 Bioverativ Therapeutics Inc Thrombin cleavable linker with xten and its uses thereof
EP3875106A1 (de) 2013-08-08 2021-09-08 Bioverativ Therapeutics Inc. Reinigung von chimären fviii-molekülen
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
EP3065769A4 (de) 2013-11-08 2017-05-31 Biogen MA Inc. Prokoagulatorische fusionsverbindung
WO2015085276A1 (en) 2013-12-06 2015-06-11 Biogen Idec Ma Inc. Population pharmacokinetics tools and uses thereof
CN116621991A (zh) 2014-01-10 2023-08-22 比奥贝拉蒂治疗公司 因子viii嵌合蛋白及其用途
EP3102589A1 (de) 2014-02-04 2016-12-14 Biogen MA Inc. Verwendung von kationenaustauscherchromatographie im durchflussmodus zur anreicherung von posttranslationalen modifikationen
CN106414492B (zh) 2014-06-06 2021-07-06 奥克塔法马股份有限公司 包含因子viii和冯·维勒布兰德因子肽的制剂
US9987241B2 (en) 2014-09-25 2018-06-05 The Board Of Regents Of The University Of Oklahoma Enzyme conjugate and prodrug cancer therapy
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
CN108884145B (zh) 2015-11-13 2023-08-22 武田药品工业株式会社 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
JP6695426B2 (ja) 2015-11-13 2020-05-20 バクスアルタ インコーポレイテッド 組換えｆｖｉｉｉ変異型をコードする血友病ａ遺伝子治療用高発現ウイルスベクター
PL3411478T3 (pl) 2016-02-01 2022-10-03 Bioverativ Therapeutics Inc. Geny zoptymalizowanego czynnika VIII
WO2017222337A1 (ko) 2016-06-24 2017-12-28 재단법인 목암생명과학연구소 Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
JP2020504082A (ja) 2016-11-11 2020-02-06 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド
EP3548066A1 (de) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc. Verfahren zur behandlung von hämophile arthropathie unter verwendung chimärer gerinnungsfaktoren
MX2019006446A (es) 2016-12-02 2019-12-11 Bioverativ Therapeutics Inc Métodos para inducir tolerancia inmunológica a factores de coagulación.
SG11202000764RA (en) 2017-08-09 2020-02-27 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
US11446365B2 (en) 2017-08-09 2022-09-20 The Board Of Regents Of The University Of Oklahoma Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
US20210038744A1 (en) 2018-02-01 2021-02-11 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor viii
IL277713B2 (en) 2018-04-04 2024-09-01 Sigilon Therapeutics Inc Implantable particles and related methods
SG11202010767SA (en) 2018-05-18 2020-11-27 Bioverativ Therapeutics Inc Methods of treating hemophilia a
TW202006141A (zh) 2018-07-16 2020-02-01 美商巴克斯歐塔公司 使用編碼具有增加表現的重組fviii變異體之病毒載體的a型血友病之基因療法
BR112021002017A2 (pt) 2018-08-09 2021-05-11 Bioverativ Therapeutics Inc. moléculas de ácido nucleico e usos das mesmas para terapia genética não viral
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
EA202191977A1 (ru) 2019-01-16 2021-12-15 Баксалта Инкорпорейтед Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии а
BR112021025426A2 (pt) 2019-06-19 2022-06-21 Bioverativ Therapeutics Inc Fator recombinante viii-fc para tratamento de hemofilia e baixa densidade mineral óssea
US20230023826A1 (en) 2019-12-12 2023-01-26 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
WO2021165226A1 (en) 2020-02-17 2021-08-26 Biotest Ag Subcutaneous administration of factor viii
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction
EP4355768A1 (de) 2021-06-14 2024-04-24 Takeda Pharmaceutical Company Limited Gentherapie von hämophilie a unter verwendung von für rekombinante fviii-varianten codierenden viralen vektoren mit erhöhter expression
WO2023028456A1 (en) 2021-08-23 2023-03-02 Bioverativ Therapeutics Inc. Optimized factor viii genes
WO2023056331A1 (en) 2021-09-30 2023-04-06 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4027013A (en) * 1976-01-22 1977-05-31 William L. Wilson Clottable fibrinogen free factor VIII and albumin product and process
US4348384A (en) * 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US4495175A (en) * 1982-08-05 1985-01-22 University Of Rochester Preparation of highly purified human antihemophilic factor
US4746508A (en) * 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
IL74909A (en) * 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
ES8801674A1 (es) * 1985-04-12 1988-02-16 Genetics Inst Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante.
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5576194A (en) * 1986-07-11 1996-11-19 Bayer Corporation Recombinant protein production
NO872932L (no) * 1986-07-18 1988-01-19 Gist Brocades Nv Fremgangsmaate for fremstilling av proteiner med faktorviiiaktivitet ved hjelp av mikrobielle vertsceller, eksprimeringsvektorer, vertsceller, antibiotika.
US5171844A (en) * 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
FR2619314B1 (fr) * 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5204323B1 (en) * 1988-10-06 1995-07-18 Ciba Geigy Corp Hirudin antidotal compositions and methods
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
SE468050C (sv) * 1991-03-15 1998-04-27 Pharmacia & Upjohn Ab Rekombinant derivat av human faktor VIII
DE4111393A1 (de) † 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
GB9122609D0 (en) † 1991-10-24 1991-12-04 Brownlee George G Improvements relating to the treatment of haemophilia
GB9211538D0 (en) * 1992-06-01 1992-07-15 Blake David R Antiinflammatory agent
ATE198277T1 (de) † 1992-10-02 2001-01-15 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
US5563045A (en) * 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
AU5602394A (en) * 1992-11-13 1994-06-08 Duke University Chimeric blood coagulation proteins
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation

Also Published As

Publication number Publication date
ES2193159T5 (es) 2011-07-29
DE69432179T2 (de) 2003-07-24
SE9302308L (sv) 1995-01-06
EP0710114A1 (de) 1996-05-08
CA2163112A1 (en) 1995-01-19
SE9302308D0 (sv) 1993-07-05
DE69432179D1 (de) 2003-04-03
MX9402339A (es) 1995-01-31
WO1995001804A1 (en) 1995-01-19
ATE233099T1 (de) 2003-03-15
DK0710114T3 (da) 2003-06-23
AU6762794A (en) 1995-02-06
PT710114E (pt) 2003-06-30
EP0710114B2 (de) 2011-03-16
EP0710114B1 (de) 2003-02-26
JPH09500624A (ja) 1997-01-21
ES2193159T3 (es) 2003-11-01
DE69432179T3 (de) 2012-01-19
JP3827713B2 (ja) 2006-09-27
CA2163112C (en) 2007-08-07
SE9401105D0 (sv) 1994-03-31
ZA942035B (en) 1995-01-05
US5972885A (en) 1999-10-26
DK0710114T4 (da) 2011-07-11

Similar Documents

Publication Publication Date Title
SE504074C2 (sv) Proteinberedning för subkutan, intramuskulär eller intradermal administrering
EP0314095B1 (de) Plasma- und Rekombinationsproteinformulierungen in einem Milieu hoher Ionenstärke
EP0315968B2 (de) Plasma- und Rekombinationsproteinformulierungen in einem Milieu niedriger Ionenstärke
EP0700299B1 (de) Sauerstoff reduzierte wässerige faktor viii-enthaltene lösung
US5605884A (en) Factor VIII formulations in high ionic strength media
JP3939750B2 (ja) 凝固第ｖｉｉｉ因子の皮下、筋肉内または皮内投与用の製薬調合剤
EP0638091B1 (de) Verbesserte solubilisierung und stabilisierung des faktor viii-komplexes
JP3777467B2 (ja) 安定化第ｖｉｉｉ因子調製物
JP2000504327A (ja) 高度に濃縮された、凍結乾燥された、および液体の、因子▲ｉｘ▼処方
HU211670A9 (en) Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
JP3927248B2 (ja) Ｈｇｆ凍結乾燥製剤
EP0410207B1 (de) Stabilisierung von hochgereinigten Proteinen
AU2772092A (en) Treatment of haemophilia
US20020146409A1 (en) Methods for stabilizing lyophilized blood proteins

Legal Events

Date Code Title Description
NUG Patent has lapsed